MAM
Imax inks partnership with Vue International for Denmark’s first Imax theatre
MUMBAI: Imax Corporation and Vue International have inked an agreement for an Imax theatre to be added to the CinemaxX multiplex in Copenhagen, Denmark. The deal marks Imax’s first commercial theatre agreement in Denmark.
“We are committed to delivering premium entertainment experiences and Imax is an extension of this strategy, serving as the anchor attraction for our multiplex in Copenhagen. We are absolutely delighted to be the first to bring audiences in Denmark, Imax, the world’s most immersive way to experience the biggest blockbuster films, which we are confident will further strengthen our business and thrill our guests for many more years to come,” said Vue International CEO Tim Richards.
“With its strong movie-going culture and growing exhibition industry, Denmark is a very promising market for us. I can’t think of a better way to enter the commercial market in Denmark than by partnering with a first class exhibitor to bring Imax to the nation’s most successful cinema complex, hosting the biggest screen in Scandinavia,” added Imax EMEA president Andrew Cripps.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
